Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
1.
Int Ophthalmol ; 39(6): 1355-1366, 2019 Jun.
Article in English | MEDLINE | ID: mdl-29922978

ABSTRACT

PURPOSE: Conventional dosage form like eye drops showed poor therapeutic response and also require frequent dosing. Therefore, developing the dosage form to deliver the drug to the target site without much loss of drug or without causing any systemic side effects is the challenging job for the researchers in pharmaceutical industries. OBJECTIVE: The main aim of the present work was to formulate and evaluate hydrogel-based drug delivery containing combination of neomycin sulphate and betamethasone sodium phosphate in order to provide prolonged release and also better bioavailability of drugs for the treatment of eye infections. METHODS: In this study, poloxamer 407 and chitosan at different concentrations were used as the gelling agents. The prepared formulations were evaluated for clarity, pH, drug content, gelling capacity, gelling temperature and in vitro drug release study. RESULTS: From the preliminary studies, F5 formulation was selected as an optimized formulation. The optimized formulation was further evaluated for ex vivo permeation study, sterility test, HET-CAM and ocular irritation testing using rabbits. Ocular irritation by HET-CAM assay showed that the formulated gel does not cause any irritation to the blood vessels. Draize irritation test was performed using rabbits and results showed that formulation was non-irritant to the eye. CONCLUSION: The formulated hydrogel formulation can be used as an alternative to conventional ophthalmic eye drop formulation of drugs neomycin and betamethasone for the purpose of providing prolonged therapy for the treatment of conjunctivitis.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Betamethasone/analogs & derivatives , Conjunctivitis/drug therapy , Drug Delivery Systems/methods , Glucocorticoids/administration & dosage , Hydrogels/chemistry , Neomycin/administration & dosage , Animals , Anti-Bacterial Agents/pharmacokinetics , Betamethasone/administration & dosage , Betamethasone/pharmacokinetics , Biological Availability , Chitosan/chemistry , Disease Models, Animal , Eye Infections/drug therapy , Glucocorticoids/pharmacokinetics , Neomycin/pharmacokinetics , Poloxamer/chemistry , Rabbits
2.
Histochem Cell Biol ; 150(3): 281-289, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29862415

ABSTRACT

Aminoglycoside ototoxicity results in permanent loss of the sensory hair cells in the mammalian cochlea. It usually begins at the basal turn causing high-frequency hearing loss. Here we describe previously unreported resistance of hair cells to neomycin ototoxicity in the extreme basal (hook) region of the developing cochlea of the C57BL/6 mouse. Organ of Corti explants from mice at postnatal day 3 were incubated (37 °C, 5% CO2) in normal culture medium for 19.5 h prior to and after exposure to neomycin (1 mM, 3 h). To study neomycin uptake in the hair cells, cochlear explants were incubated with Neomycin Texas-red (NTR) conjugate. As expected, exposure to neomycin significantly reduced the survival of inner (IHC) and outer hair cells (OHC). IHC survival rate was high in the apical segment and low in the basal segment. OHC were well preserved in the apical and hook regions, with substantial OHC loss in the basal segment. The NTR uptake study demonstrated that the high survival rate in the extreme basal turn OHC was associated with low NTR uptake. Treatment with a calcium chelator (BAPTA), which disrupts the opening of mechanoelectrical (MET) transduction channels, abolished or reduced NTR uptake in the hair cells throughout the cochlea. This confirmed the essential role of MET channels in neomycin uptake and implied that the transduction channels could be impaired in the hook region of the developing mouse cochlea, possibly as a result of the cadherin 23 mutation responsible for the progressive deafness in C57BL/6 mice.


Subject(s)
Cochlea/drug effects , Hair Cells, Auditory, Outer/drug effects , Neomycin/toxicity , Animals , Cochlea/pathology , Hair Cells, Auditory, Outer/pathology , Mice , Mice, Inbred C57BL , Neomycin/chemistry , Neomycin/pharmacokinetics , Organ Culture Techniques , Tissue Distribution
3.
FASEB J ; 30(8): 2720-32, 2016 08.
Article in English | MEDLINE | ID: mdl-27059718

ABSTRACT

Given the intimate link between gut microbiota and host physiology, there is growing interest in understanding the mechanisms by which diet influences gut microbiota and affects human metabolic health. Using antibiotics and the prebiotic oligofructose, which has been shown to counteract excess fat mass, we explored the gut microbiota-dependent effects of oligofructose on body composition and host metabolism. Diet-induced obese male Sprague Dawley rats, fed a background high-fat/sucrose diet, were randomized to one of the following diets for 6 wk: 1) high-energy control; 2) 10% oligofructose; 3) ampicillin; 4) ampicillin + 10% oligofructose; 5) ampicillin/neomycin; or 6) ampicillin/neomycin + 10% oligofructose. Combining oligofructose with ampicillin treatment blunted the decrease in adiposity seen with oligofructose. Although ampicillin did not affect total bacteria, ampicillin impeded oligofructose-induced increases in Bifidobacterium and Lactobacillus In contrast, the combination of ampicillin and neomycin reduced total bacteria but did not abrogate the oligofructose-induced decrease in adiposity. Oligofructose-mediated effects on host adiposity and metabolic health appear to be in part dependent on the presence of specific microbial species within the gut.-Bomhof, M. R., Paul, H. A., Geuking, M. B., Eller, L. K., Reimer, R. A. Improvement in adiposity with oligofructose is modified by antibiotics in obese rats.


Subject(s)
Adiposity/drug effects , Ampicillin/pharmacokinetics , Neomycin/pharmacokinetics , Obesity/drug therapy , Oligosaccharides/pharmacology , Oligosaccharides/pharmacokinetics , Ampicillin/administration & dosage , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Bacteria/drug effects , Bacteria/genetics , Bacteria/isolation & purification , Blood Glucose , Energy Intake , Glucose Tolerance Test , Male , Neomycin/administration & dosage , Oligosaccharides/administration & dosage , RNA, Ribosomal, 16S , Rats , Rats, Sprague-Dawley
4.
Mol Pharm ; 10(5): 1964-76, 2013 May 06.
Article in English | MEDLINE | ID: mdl-23510087

ABSTRACT

A straightforward methodology for the synthesis of conjugates between a cytotoxic organometallic ruthenium(II) complex and amino- and guanidinoglycosides, as potential RNA-targeted anticancer compounds, is described. Under microwave irradiation, the imidazole ligand incorporated on the aminoglycoside moiety (neamine or neomycin) was found to replace one triphenylphosphine ligand from the ruthenium precursor [(η(6)-p-cym)RuCl(PPh3)2](+), allowing the assembly of the target conjugates. The guanidinylated analogue was easily prepared from the neomycin-ruthenium conjugate by reaction with N,N'-di-Boc-N″-triflylguanidine, a powerful guanidinylating reagent that was compatible with the integrity of the metal complex. All conjugates were purified by semipreparative high-performance liquid chromatography (HPLC) and characterized by electrospray ionization (ESI) and matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) and NMR spectroscopy. The cytotoxicity of the compounds was tested in MCF-7 (breast) and DU-145 (prostate) human cancer cells, as well as in the normal HEK293 (Human Embryonic Kidney) cell line, revealing a dependence on the nature of the glycoside moiety and the type of cell (cancer or healthy). Indeed, the neomycin-ruthenium conjugate (2) displayed moderate antiproliferative activity in both cancer cell lines (IC50 ≈ 80 µM), whereas the neamine conjugate (4) was inactive (IC50 ≈ 200 µM). However, the guanidinylated analogue of the neomycin-ruthenium conjugate (3) required much lower concentrations than the parent conjugate for equal effect (IC50 = 7.17 µM in DU-145 and IC50 = 11.33 µM in MCF-7). Although the same ranking in antiproliferative activity was found in the nontumorigenic cell line (3 ≫ 2 > 4), IC50 values indicate that aminoglycoside-containing conjugates are about 2-fold more cytotoxic in normal cells (e.g., IC50 = 49.4 µM for 2) than in cancer cells, whereas an opposite tendency was found with the guanidinylated conjugate, since its cytotoxicity in the normal cell line (IC50 = 12.75 µM for 3) was similar or even lower than that found in MCF-7 and DU-145 cancer cell lines, respectively. Cell uptake studies performed by ICP-MS with conjugates 2 and 3 revealed that guanidinylation of the neomycin moiety had a positive effect on accumulation (about 3-fold higher in DU-145 and 4-fold higher in HEK293), which correlates well with the higher antiproliferative activity of 3. Interestingly, despite the slightly higher accumulation in the normal cell than in the cancer cell line (about 1.4-fold), guanidinoneomycin-ruthenium conjugate (3) was more cytotoxic to cancer cells (about 1.8-fold), whereas the opposite tendency applied for neomycin-ruthenium conjugate (2). Such differences in cytotoxic activity and cellular accumulation between cancer and normal cells open the way to the creation of more selective, less toxic anticancer metallodrugs by conjugating cytotoxic metal-based complexes such as ruthenium(II) arene derivatives to guanidinoglycosides.


Subject(s)
Antineoplastic Agents/chemistry , Neomycin/analogs & derivatives , Organometallic Compounds/chemistry , Ruthenium/chemistry , Aminoglycosides/chemistry , Aminoglycosides/pharmacokinetics , Aminoglycosides/pharmacology , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/pharmacology , Biological Transport, Active , Cell Line, Tumor , Cell Proliferation/drug effects , Female , HEK293 Cells , Humans , MCF-7 Cells , Male , Neomycin/pharmacokinetics , Neomycin/pharmacology , Organometallic Compounds/pharmacokinetics , Organometallic Compounds/pharmacology , RNA, Neoplasm/drug effects , RNA, Neoplasm/metabolism , Ruthenium/pharmacokinetics , Ruthenium/pharmacology
5.
J Nanobiotechnology ; 9: 58, 2011 Dec 20.
Article in English | MEDLINE | ID: mdl-22185583

ABSTRACT

BACKGROUND: Targeted drug-carrying phage nanomedicines are a new class of nanomedicines that combines biological and chemical components into a modular nanometric drug delivery system. The core of the system is a filamentous phage particle that is produced in the bacterial host Escherichia coli. Target specificity is provided by a targeting moiety, usually an antibody that is displayed on the tip of the phage particle. A large drug payload is chemically conjugated to the protein coat of the phage via a chemically or genetically engineered linker that provides for controlled release of the drug after the particle homed to the target cell. Recently we have shown that targeted drug-carrying phage nanomedicines can be used to eradicate pathogenic bacteria and cultured tumor cells with great potentiation over the activity of the free untargeted drug. We have also shown that poorly water soluble drugs can be efficiently conjugated to the phage coat by applying hydrophilic aminoglycosides as branched solubility-enhancing linkers. RESULTS: With an intention to move to animal experimentation of efficacy, we tested anti-bacterial drug-carrying phage nanomedicines for toxicity and immunogenicity and blood pharmacokinetics upon injection into mice. Here we show that anti-bacterial drug-carrying phage nanomedicines that carry the antibiotic chloramphenicol conjugated via an aminoglycoside linker are non-toxic to mice and are greatly reduced in immunogenicity in comparison to native phage particles or particles to which the drug is conjugated directly and are cleared from the blood more slowly in comparison to native phage particles. CONCLUSION: Our results suggest that aminoglycosides may serve as branched solubility enhancing linkers for drug conjugation that also provide for a better safety profile of the targeted nanomedicine.


Subject(s)
Bacteriophages/chemistry , Drug Carriers/chemistry , Nanomedicine , Animals , Mice , Neomycin/administration & dosage , Neomycin/pharmacokinetics
7.
Ear Hear ; 30(1): 81-9, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19125030

ABSTRACT

OBJECTIVE: Establishing methods for topical administration of drugs to the inner ear have great clinical relevance and potential even in a relatively short perspective. To evaluate the efficacy of sodium hyaluronate (HYA) as a vehicle for drugs that could be used for treatment of inner ear disorders. METHODS: The cochlear hair cell loss and round window membrane (RWM) morphology were investigated after topical application of neomycin and HYA into the middle ear. Sixty-five albino guinea pigs were used and divided into groups depending on the type of the treatment. Neomycin was chosen as tracer for drug release and pharmacodynamic effect. HYA loaded with 3 different concentrations of neomycin was injected to the middle ear cavity of guinea pigs. Phalloidin stained surface preparations of the organ of Corti were used to estimate hair cell loss induced by neomycin. The thickness of the midportion of the RWM was measured and compared with that of controls using light and electron microscopy. All animal procedures were pe rformed in accordance with the ethical standards of Karolinska Institutet. RESULT: Neomycin induced a considerable hair cell loss in guinea pigs receiving a middle ear injection of HYA loaded with the drug, demonstrating that neomycin was released from the gel and delivered to the inner ear. The resulting hair cell loss showed a clear dose-dependence. Only small differences in hair cell loss were noted between animals receiving neomycin solution and animals exposed to neomycin in HYA suggesting that the vehicle neither facilitated nor hindered drug transport between the middle ear cavity and the inner ear. One week after topical application, the thickness of the RWM had increased and was dependent upon the concentration of neomycin administered to the middle ear. At 4 weeks the thickness of the RWM had returned to normal. CONCLUSION: HYA is a safe vehicle for drugs aimed to pass into the inner ear through the RWM. Neomycin was released from HYA and transported into the inner ear as evidenced by hair cell loss.


Subject(s)
Ear, Middle , Hyaluronic Acid , Neomycin/administration & dosage , Animals , Biological Transport/drug effects , Cell Death , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Ear Diseases/drug therapy , Ear, Inner/metabolism , Ear, Middle/metabolism , Gels , Guinea Pigs , Hair Cells, Auditory/drug effects , Hair Cells, Auditory/physiology , Hyaluronic Acid/pharmacology , Injections , Neomycin/pharmacokinetics , Pharmaceutical Vehicles/pharmacology , Round Window, Ear/drug effects , Round Window, Ear/metabolism , Round Window, Ear/pathology
8.
J Biol Chem ; 282(18): 13585-91, 2007 May 04.
Article in English | MEDLINE | ID: mdl-17311923

ABSTRACT

Facilitating the uptake of molecules into living cells is of substantial interest for basic research and drug delivery applications. Arginine-rich peptides have been shown to facilitate uptake of high molecular mass cargos into cells, but the mechanism of uptake is complex and may involve multiple receptors. In this report, we show that a derivative of the aminoglycoside antibiotic neomycin, in which all of the ammonium groups have been converted into guanidinium groups, can carry large (>300 kDa) bioactive molecules across cell membranes. Delivery occurs at nanomolar transporter concentrations and under these conditions depends entirely on cell surface heparan sulfate proteoglycans. Conjugation of guanidinoneomycin to the plant toxin saporin, a ribosome-inactivating agent, results in proteoglycan-dependent cell toxicity. In contrast, an arginine-rich peptide shows both heparan sulfate-dependent and -independent cellular uptake. The high selectivity of guanidinoneomycin for heparan sulfate suggests the possibility of exploiting differences in proteoglycan compositions to target delivery to different cell types.


Subject(s)
Drug Delivery Systems , Heparan Sulfate Proteoglycans/metabolism , Membrane Glycoproteins/metabolism , Neomycin/pharmacokinetics , Protein Synthesis Inhibitors/pharmacokinetics , Animals , Biological Transport/drug effects , Biological Transport/physiology , CHO Cells , Cricetinae , Cricetulus , Dose-Response Relationship, Drug , Guanidine/analogs & derivatives , Guanidine/chemical synthesis , Guanidine/pharmacokinetics , N-Glycosyl Hydrolases/pharmacokinetics , Neomycin/analogs & derivatives , Neomycin/chemical synthesis , Peptides/chemical synthesis , Peptides/pharmacokinetics , Plant Proteins/pharmacokinetics , Protein Binding/drug effects , Protein Synthesis Inhibitors/chemical synthesis , Ribosome Inactivating Proteins, Type 1 , Saporins
10.
Braz Oral Res ; 18(2): 174-9, 2004.
Article in English | MEDLINE | ID: mdl-15311323

ABSTRACT

The objective of this study was to evaluate the irritant potential of propolis, Casearia sylvestris, Otosporin and saline solution (control). Twenty-eight male Wistar rats were selected, anesthetized and four experimental sites were designed on their backs. Injections of 2% Evans blue were intravenously administered in the lateral caudal vein and 0.1 ml of the tested solutions was injected intradermally into the experimental sites. The animals were killed 1/2, 1, 3 and 6 hours after the injection of the solutions. Each piece of skin containing the lesion was immersed in formamide and incubated at 45 masculine C for 72 h. After filtration, optical density was measured in a spectrophotometer. Data were statistically analyzed by a 2-way non-parametric test. The highest values of extracted dye were observed at 3 hours characterizing a peak in the inflammatory process. Propolis was the least irritant solution. The natural medicaments tested in this study may be a valuable alternative for endodontic treatment.


Subject(s)
Anti-Inflammatory Agents/adverse effects , Capillary Permeability , Casearia , Dental Pulp Cavity/drug effects , Phytotherapy , Propolis/adverse effects , Animals , Anti-Infective Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Coloring Agents/pharmacokinetics , Drug Combinations , Evans Blue/pharmacokinetics , Hydrocortisone/pharmacokinetics , Inflammation/drug therapy , Inflammation/metabolism , Male , Neomycin/pharmacokinetics , Polymyxin B/pharmacokinetics , Propolis/therapeutic use , Rats , Rats, Wistar , Sodium Chloride/pharmacology
11.
Methods Find Exp Clin Pharmacol ; 26(4): 257-62, 2004 May.
Article in English | MEDLINE | ID: mdl-15319803

ABSTRACT

The effect of phospholipid and MgATPase modulation was evaluated on the cardiovascular actions of vasopressin in normal and lithium carbonate- (Li2CO3) induced polyuric rats. We examined the effects of the phospholipase inhibitor neomycin, the diacylglycerol kinase II inhibitor R59949 and the MgATPase activator sphingosine on heart rate (HR) and blood pressure (BP) responses to vasopressin analogues lysine vasopressin (LVP) and arginine vasopressin (AVP). R59949 (20 microg/kg) produced an increase while sphingosine (30 microg/kg) caused a decrease in HR responses in both control and polyuric rats. Pretreatment with sphingosine caused significant enhancement of LVP- (10 microg/kg) induced bradycardia in polyuria rats compared with control animals (p < 0.01). R59949 induced a potentiation of vasopressin-induced bradycardia in control animals compared with polyuria rats. Pretreatment with sphingosine and R59949 produced a significant increase in BP per se and potentiated the actions of LVP in control animals, while the response in the lithium-treated animals was attenuated. Neomycin caused a reduction in HR and BP in control and lithium-treated animals. To evaluate the central role of the MgATPase enzyme we used sphingosine, which significantly increased the locomotor activity of lithium-treated animals, suggesting a possible central interaction of lithium and MgATPase (p < 0.05). These results strongly suggest that phospholipid mediators and MgATPase modulation contribute to the alteration of the cardiovascular effects of vasopressin in lithium carbonate-induced polyuric rats.


Subject(s)
Arginine Vasopressin/pharmacokinetics , Blood Pressure/drug effects , Ca(2+) Mg(2+)-ATPase/metabolism , Heart Rate/drug effects , Lithium Carbonate/adverse effects , Lypressin/pharmacology , Phospholipids/metabolism , Polyuria/chemically induced , Animals , Arginine Vasopressin/administration & dosage , Disease Models, Animal , Drug Synergism , Drug Therapy, Combination , Injections, Intraperitoneal , Injections, Intravenous , Lithium Carbonate/administration & dosage , Lithium Carbonate/metabolism , Lypressin/antagonists & inhibitors , Lypressin/metabolism , Mice , Motor Activity/drug effects , Neomycin/administration & dosage , Neomycin/pharmacokinetics , Piperidines/administration & dosage , Piperidines/pharmacokinetics , Quinazolines/administration & dosage , Quinazolines/pharmacokinetics , Quinazolinones , Rats , Rats, Wistar , Sphingosine/administration & dosage , Sphingosine/pharmacokinetics
12.
Hear Res ; 172(1-2): 92-8, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12361871

ABSTRACT

We have developed a novel scala tympani electrode array suitable for use in experimental animals. A unique feature of this array is its ability to chronically deliver pharmacological agents to the scala tympani. The design of the electrode array is described in detail. Experimental studies performed in guinea pigs confirm that this array can successfully deliver various drugs to the cochlea while chronically stimulating the auditory nerve.


Subject(s)
Cochlea/drug effects , Infusion Pumps, Implantable , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/toxicity , Cochlea/injuries , Cochlea/pathology , Cochlea/physiopathology , Cochlear Nerve/physiology , Electric Stimulation , Equipment Design , Evoked Potentials, Auditory, Brain Stem/drug effects , Guinea Pigs , Microelectrodes , Neomycin/administration & dosage , Neomycin/pharmacokinetics , Neomycin/toxicity , Scala Tympani
13.
Acta Pol Pharm ; 59(3): 181-6, 2002.
Article in English | MEDLINE | ID: mdl-12230244

ABSTRACT

The subject of the studies was eye drops made of aloe, containing the group of aloe chemical substances of anti-inflammatory use and neomycin sulphate. The aim of the studies was to evaluate the permeability of biologically active aloe substances, determined as aloenin, through synthetic lipophilic and hydrophilic membranes in a standard perfusion apparatus and in vitro verification of the transport possibilities of these substances through the isolated cornea of pig's eye. The permeability process of biologically active aloe substances determined as aloenin, through synthetic lipophilic and hydrophilic membranes, was analyzed using the first-order kinetics. Estimated quotas of permeability rate constant show that the investigated chemical compounds of aloe, included in the eye drops, diffused through the applied membranes. The studies of permeability through isolated pig's cornea proved that biologically active aloe substances could not overcome this biological barrier. On the basis of biopharmaceutical studies it can be concluded that the eye drops containing aloe and neomycin sulphate, due to the lack of permeating abilities through the eye cornea, should be particularly useful in the treatment of inflammations and infections of external parts of the eye, such as conjuctiva, eyelid edges, lacrimal sac and cornea.


Subject(s)
Aloe , Neomycin/pharmacokinetics , Ophthalmic Solutions/pharmacokinetics , Aloe/chemistry , Animals , Biopharmaceutics , Cornea/metabolism , Neomycin/analysis , Neomycin/chemistry , Ophthalmic Solutions/analysis , Ophthalmic Solutions/chemistry , Plant Extracts/analysis , Plant Extracts/chemistry , Plant Extracts/pharmacokinetics , Plant Leaves/chemistry , Swine
14.
Otolaryngol Head Neck Surg ; 122(3): 330-3, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10699804

ABSTRACT

The treatment of patients with tympanostomy tubes (TTs) and otorrhea with medicated otic suspensions is well known, but confirmation of penetration into the middle ear is difficult. To address this question, we created an in vitro model of the human head and ear and then tested it with 5 different types of liquid exposure: tap water, soapy water, polymyxin B sulfate (Cortisporin), tobramycin and dexamethasone (TobraDex), and ciprofloxacin (Cipro) suspensions. A positive test result corresponded to liquids entering the middle ear through the TT. No positive test result was elicited with tap water (0/20), but soapy water did enter the middle ear (10/40) and was statistically significant (P = 0.0112). Without the use of slight tragal pressure, Cortisporin, TobraDex, and Cipro drops did not consistently pass through the TT (0/20, 1/25, 1/25). By placing the drops with the addition of tragal pressure, a statistically significant difference was obtained for each solution (20/20, 20/20, and 20/20, respectively [P < 0.0001]). We conclude that with a clean external auditory canal, patent TT, and no middle ear fluid, medicated otic suspensions enter the middle ear only when combined with slight tragal pressure.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Ear, Middle/metabolism , Middle Ear Ventilation , Otitis Media, Suppurative/drug therapy , Postoperative Complications/drug therapy , Therapeutic Irrigation , Administration, Topical , Anti-Bacterial Agents/administration & dosage , Ciprofloxacin/administration & dosage , Ciprofloxacin/pharmacokinetics , Dexamethasone/administration & dosage , Dexamethasone/pharmacokinetics , Drug Combinations , Ear, Middle/drug effects , Humans , Hydrocortisone/administration & dosage , Hydrocortisone/pharmacokinetics , Neomycin/administration & dosage , Neomycin/pharmacokinetics , Otitis Media, Suppurative/metabolism , Polymyxin B/administration & dosage , Polymyxin B/pharmacokinetics , Postoperative Complications/metabolism , Tobramycin/administration & dosage , Tobramycin/pharmacokinetics
15.
J Physiol ; 512 ( Pt 1): 29-46, 1998 Oct 01.
Article in English | MEDLINE | ID: mdl-9729615

ABSTRACT

1. The effects of neomycin on NMDA-evoked currents in isolated CA1 hippocampal pyramidal neurones were investigated and single channel activity was examined in outside-out patches taken from cultured hippocampal neurones. The effects of neomycin on two combinations of NMDA receptor subunits (NR1a-NR2A and NR1a-NR2B) expressed in human embryonic kidney (HEK293) cells were also studied. 2. Neomycin (0. 01-1 mM) caused a potentiation of NMDA-activated currents in all neurones examined. No evidence of a voltage-dependent depression was observed in whole-cell recordings. 3. In outside-out patch recordings relatively low concentrations (30 and 100 microM) of neomycin caused a voltage-dependent reduction in single channel current amplitude as well as a large increase in the frequency of channel opening. 4. In saturating concentrations of glycine, neomycin enhanced NMDA-activated currents and this glycine-independent enhancement was confirmed using recombinant NR1a-NR2B receptors. Neomycin substantially increased the potency of glycine for the receptor by reducing the rate of dissociation of glycine from the receptor. Neomycin demonstrated a glycine-dependent enhancement of currents mediated by the NR1a-NR2A combination of subunits but a paradoxical depression was observed in saturating concentrations of glycine. 5. Neomycin increased the rate of deactivation of glutamate-activated currents consistent with neomycin causing a reduction in the affinity of the receptor for agonist. 6. These results indicate that neomycin has multiple and complex effects on NMDA receptors.


Subject(s)
Hippocampus/physiology , Magnesium/pharmacology , Neomycin/pharmacology , Pyramidal Cells/physiology , Receptors, N-Methyl-D-Aspartate/physiology , Spermine/pharmacology , Animals , Binding Sites , Calcium/pharmacology , Cell Line , Cells, Cultured , Evoked Potentials/drug effects , Glutamic Acid/pharmacology , Glycine/pharmacology , Hippocampus/cytology , Humans , Magnesium/metabolism , N-Methylaspartate/pharmacology , Neomycin/pharmacokinetics , Pyramidal Cells/cytology , Pyramidal Cells/drug effects , Rats , Receptors, N-Methyl-D-Aspartate/chemistry , Receptors, N-Methyl-D-Aspartate/drug effects , Spermine/pharmacokinetics , Transfection
17.
J Neurosci ; 17(24): 9506-19, 1997 Dec 15.
Article in English | MEDLINE | ID: mdl-9391006

ABSTRACT

Myosin VIIA is expressed by sensory hair cells and has a primary structure predicting a role in membrane trafficking and turnover, processes that may underlie the susceptibility of hair cells to aminoglycoside antibiotics. [3H]Gentamicin accumulation and the effects of aminoglycosides were therefore examined in cochlear cultures of mice with different missense mutations in the myosin VIIA gene, Myo7a, to see whether myosin VIIA plays a role in aminoglycoside ototoxicity. Hair cells from homozygous mutant Myo7ash1 mice, with a mutation in a nonconserved region of the myosin VIIA head, respond rapidly to aminoglycoside treatment and accumulate high levels of gentamicin. Hair cells from homozygous mutant Myo7a6J mice, with a mutation at a highly conserved residue close to the ATP binding site of the myosin VIIA head, do not accumulate [3H]gentamicin and are protected from aminoglycoside ototoxicity. Hair cells from heterozygotes of both alleles accumulate [3H]gentamicin and respond to aminoglycosides. Although aminoglycoside uptake is thought to be via apical surface-associated endocytosis, coated pit numbers on the apical membrane of heterozygous and homozygous Myo7a6J hair cells are similar. Pulse-chase experiments with cationic ferritin confirm that the apical endocytotic pathway is functional in homozygous Myo7a6J hair cells. Transduction currents can be recorded from both heterozygous and homozygous Myo7a6J hair cells, suggesting it is unlikely that the drug enters via diffusion through the mechanotransducer channel. The results show that myosin VIIA is required for aminoglycoside accumulation in hair cells. Myosin VIIA may transport a putative aminoglycoside receptor to the hair cell surface, indirectly translocate it to sites of membrane retrieval, or retain it in the endocytotic pathway.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Gentamicins/pharmacokinetics , Hair Cells, Auditory, Outer/metabolism , Myosins/genetics , Neomycin/pharmacokinetics , Adenosine Triphosphate/metabolism , Amino Acid Substitution/physiology , Animals , Animals, Newborn , Anti-Bacterial Agents/adverse effects , Binding Sites/physiology , Cell Membrane/drug effects , Cell Membrane/metabolism , Cell Membrane/ultrastructure , Cells, Cultured , Dyneins , Endocytosis/drug effects , Freeze Fracturing , Gentamicins/adverse effects , Hair Cells, Auditory, Outer/cytology , Hair Cells, Auditory, Outer/drug effects , Mice , Microscopy, Electron , Microscopy, Electron, Scanning , Myosin VIIa , Myosins/metabolism , Neomycin/adverse effects , Point Mutation , Tritium
18.
J Otolaryngol ; 26(6): 357-60, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9438931

ABSTRACT

OBJECTIVE: The use of intranasal ointment sniffed into the nasal cavity is widely recommended as a method to lubricate the nose and to prevent drying and crusting of the nasal mucosa and secretions. This therapy is often prescribed to patients with problems with minor episodes of epistaxis, after nasal packing has been removed, and in patients complaining of excessive dryness or crusting within the nose. Various preparations have been used for this purpose. At our institution Polysporin ointment is one of the commonly used preparations. This study evaluated the distribution of Polysporin ointment within the nasal cavities of subjects with no symptoms related to the nasal cavity. CONCLUSIONS: The results of the study raise doubts about the effectiveness of this therapy.


Subject(s)
Anti-Infective Agents, Local/pharmacokinetics , Drug Therapy, Combination/pharmacokinetics , Nasal Cavity/metabolism , Ointments/pharmacokinetics , Adult , Anti-Infective Agents, Local/administration & dosage , Bacitracin/administration & dosage , Bacitracin/pharmacokinetics , Drug Combinations , Drug Therapy, Combination/administration & dosage , Humans , Neomycin/administration & dosage , Neomycin/pharmacokinetics , Ointments/administration & dosage , Polymyxin B/administration & dosage , Polymyxin B/pharmacokinetics
20.
Vet. Méx ; 26(1): 1-15, ene.-mar. 1995. tab
Article in Spanish | LILACS | ID: lil-173865

ABSTRACT

Dada la importancia de los aminoglicósidos y aminocilitoles en la clínica veterinaria, y en virtud de la enorme cantidad de información que se genera en torno a estos antimicrobianos, se consideró de importancia llevar a cabo un análisisi farmacológico y clínico de la literatura especializada. La intención primordial de realizar estudios documentales de esta naturaleza es estrechar las actividades del clínico con las del investigador para procurar un mejor manejo de estos medicamentos en el campo, aunque también se hace énfacis en las áreas que aún requieren atención de los investigadores. Este ensayo no pretende ser enciclopédico y solamente se incluye un porcentaje del enorme caudal de información que se genera con estos dos grupos de antimicrobianos. Se hace énfasis en los aspectos farmacológicos que pueden ser de importancia para el clínico, incluyendo rasgos generales de los grupos, datos farmacocinéticos, de espectro, residuos, toxicidad y usos. Cuando resulta neceario, se presenta la opinión de los autores


Subject(s)
Tobramycin/pharmacokinetics , Bacterial Infections/veterinary , Drug Resistance, Microbial/physiology , Amikacin/pharmacokinetics , Gentamicins/pharmacokinetics , Kanamycin/pharmacokinetics , Neomycin/pharmacokinetics , Spectinomycin/pharmacokinetics , Kidney Diseases/veterinary , Aminoglycosides/pharmacology , Anti-Bacterial Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...